Fisher & Paykel Healthcare Corporation Limited (NZE: FPH)
New Zealand
· Delayed Price · Currency is NZD | Market Cap | 21.96B |
| Revenue (ttm) | 1.74B |
| Net Income (ttm) | 132.60M |
| Shares Out | 585.96M |
| EPS (ttm) | 0.23 |
| PE Ratio | 165.80 |
| Forward PE | 61.70 |
| Dividend | 0.42 (1.12%) |
| Ex-Dividend Date | Jun 26, 2024 |
| Volume | 371,035 |
| Open | 36.49 |
| Previous Close | 36.92 |
| Day's Range | 36.00 - 37.47 |
| 52-Week Range | 20.29 - 37.47 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 5, 2024 |
About FPH
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company also offers adult respiratory products, including optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition... [Read more]
Financial Performance
In 2023, FPH's revenue was 1.74 billion, an increase of 10.23% compared to the previous year's 1.58 billion. Earnings were 132.60 million, a decrease of -47.02%.
Financial StatementsNews
Fisher & Paykel ups earnings guidance as hospital rates rise
The New Zealand company says margin improvements and growing demand for its products from hospitals is driving earnings.